Capricor Therapeutics (CAPR) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- CoreWeave stock drops on dilution fears and debt concerns
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
Capricor Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update
March 17, 2016 4:00 PM EDTLOS ANGELES, March 17, 2016 /PRNewswire/ --Â Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided financial results for the fourth quarter and full year ended December 31, 2015 as well as a business update.
"In 2015 and through the early part of 2016, we expanded the scope of our clinical and preclinical programs as well as strengthened our management team with key hires," said Linda Marbán, Ph.D.,... More



